Shares of IMV stock opened at $5.86 on Thursday. IMV has a 52 week low of $3.97 and a 52 week high of $7.21.
IMV (NYSE:IMV) last announced its earnings results on Friday, November 2nd. The company reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by ($0.04). The company had revenue of $0.10 million for the quarter, compared to the consensus estimate of $0.05 million.
IMV, Inc is a clinical-stage biopharmaceutical company, which engages in the development of cancer immunotherapies and infectious disease vaccines. The firm’s patented platform, DepoVax, provides controlled and prolonged exposure of antigens and adjuvant to the immune system. The company was founded by Warwick Kimmins and Brian Lowe on March 28, 2000 and is headquartered in Halifax, Canada.
Read More: Understanding Relative Strength Index
Receive News & Ratings for IMV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IMV and related companies with MarketBeat.com's FREE daily email newsletter.